Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases.
Vigliotta I, Armuzzi S, Barone M, Solli V, Pistis I, Borsi E, Taurisano B, Mazzocchetti G, Martello M, Poletti A, Sartor C, Rizzello I, Pantani L, Tacchetti P, Papayannidis C, Mancuso K, Rocchi S, Zamagni E, Curti A, Arpinati M, Cavo M, Terragna C. Vigliotta I, et al. Front Oncol. 2022 Oct 6;12:1001048. doi: 10.3389/fonc.2022.1001048. eCollection 2022. Front Oncol. 2022. PMID: 36276072 Free PMC article.
BoBafit : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors' profiles.
Mazzocchetti G, Poletti A, Solli V, Borsi E, Martello M, Vigliotta I, Armuzzi S, Taurisano B, Zamagni E, Cavo M, Terragna C. Mazzocchetti G, et al. Among authors: vigliotta i. Comput Struct Biotechnol J. 2022 Jul 3;20:3718-3728. doi: 10.1016/j.csbj.2022.06.062. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 35891790 Free PMC article.
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Vigliotta I, Rizzello I, Rocchi S, Armuzzi S, Testoni N, Marzocchi G, Martinelli G, Cavo M, Terragna C. Martello M, et al. Among authors: vigliotta i. Blood Cancer J. 2022 Jan 26;12(1):15. doi: 10.1038/s41408-022-00610-y. Blood Cancer J. 2022. PMID: 35082295 Free PMC article.
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Sartor C, Arpinati M, Chirumbolo G, Dozza L, Cristiano G, Nanni J, Marconi G, Robustelli V, Vigliotta I, Parisi S, Terragna C, Testoni N, Paolini S, Martinelli G, Curti A, Cavo M, Papayannidis C. Sartor C, et al. Among authors: vigliotta i. Hematol Oncol. 2022 Oct;40(4):734-742. doi: 10.1002/hon.3029. Epub 2022 Jun 5. Hematol Oncol. 2022. PMID: 35618655
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Martello M, Solli V, Termini R, Kanapari A, Remondini D, Borsi E, Poletti A, Armuzzi S, Taurisano B, Vigliotta I, Mazzocchetti G, Zamagni E, Merlotti A, Tacchetti P, Pantani L, Rocchi S, Rizzello I, Mancuso K, Cavo M, Terragna C. Martello M, et al. Among authors: vigliotta i. Int J Mol Sci. 2022 Oct 18;23(20):12450. doi: 10.3390/ijms232012450. Int J Mol Sci. 2022. PMID: 36293315 Free PMC article.
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E, Mazzocchetti G, Dico AF, Vigliotta I, Martello M, Poletti A, Solli V, Armuzzi S, Taurisano B, Kanapari A, Pistis I, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Rocchi S, Rizzello I, Cavo M, Terragna C. Borsi E, et al. Among authors: vigliotta i. Clin Exp Med. 2023 Dec;23(8):5227-5239. doi: 10.1007/s10238-023-01205-y. Epub 2023 Oct 10. Clin Exp Med. 2023. PMID: 37815734 Free PMC article.
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.
Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, Kanapari A, Poletti A, Borsi E, Armuzzi S, Vigliotta I, Pistis I, Desantis V, Marzocchi G, Rizzello I, Pantani L, Mancuso K, Tacchetti P, Testoni N, Nanni C, Zamagni E, Cavo M, Terragna C. Martello M, et al. Among authors: vigliotta i. Blood Cancer J. 2024 Nov 28;14(1):208. doi: 10.1038/s41408-024-01185-6. Blood Cancer J. 2024. PMID: 39609411 Free PMC article.
13 results